Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The useful signal here is not the buy list itself; it is that the market is still paying up for AI infrastructure despite a recent factor wobble. NVDA remains the cleanest lever to hyperscaler capex, but the bigger second-order winner is AVGO if customers keep shifting toward custom silicon, networking, and integration spend rather than discrete accelerator purchases. That mix can support a higher quality multiple than peers because it monetizes more layers of the stack, not just unit shipments.

Near term, Friday weakness looks more like positioning reset than thesis damage. Over 1-3 months, the key catalyst is whether next earnings prints confirm that growth is broadening beyond one or two hyperscalers; if not, the market can still compress multiples even at 14x-19x forward earnings. The falsifier for the bull case is not valuation; it is any sign that capex cadence flattens or that margins start giving back to maintain share.

NTLA is a different animal: the opportunity is binary clinical optionality, while the risk is a long information vacuum after a safety-related trial pause. In a tape where ARKG can support momentum names, flow can help the stock bounce, but it does not remove the financing-overhang and dilution risk if timelines slip. The consensus is probably overrating "cash-rich" as a shield; in this part of biotech, time is the real balance-sheet risk.